Boustead Singapore Limited (SGX:F9D)

Ligand Pharmaceuticals Balance Sheet

Financials in millions SGD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	333.93	371.95	326.19	403.86	479.79
Short-Term Investments	12.36	5.73	7.66	89.94	10.75
Cash & Short-Term Investments	346.29	377.68	333.85	493.8	490.54
Cash Growth	-8.31%	13.13%	-32.39%	0.66%	69.11%
Accounts Receivable	148.67	209.74	219.57	180.3	228.2
Other Receivables	13.3	18.37	54.22	16.87	23.06
Receivables	184.37	247.23	290.93	211.36	268.13
Inventory	7.38	10.51	4.31	3.36	6.93
Prepaid Expenses	12.4	3.51	3.3	3.49	3.52
Other Current Assets	26.31	20.57	18.35	20.79	19.97
Total Current Assets	576.75	659.48	650.74	732.79	789.09
Property, Plant & Equipment	36.29	33.83	45.12	54.51	67.32
Long-Term Investments	349.83	263.2	250.95	110.85	123.74
Goodwill	1.28	1.26	1.21	-	-
Other Intangible Assets	1.3	1.44	4.1	0.15	1.4
Long-Term Accounts Receivable	28.44	45.77	47.58	32.69	49.86
Long-Term Deferred Tax Assets	18.84	17.44	17.09	15.28	13.6
Other Long-Term Assets	10.33	8.84	35.74	65.34	60.19
Total Assets	1,090	1,114	1,138	1,084	1,164
Accounts Payable	31.54	42.13	42.24	50.27	67.52
Accrued Expenses	49.55	47.03	32.54	38.49	49.79
Current Portion of Long-Term Debt	7.88	1.9	2.3	2.49	2.54
Current Portion of Leases	4.27	4.54	4.23	2.68	4.36
Current Income Taxes Payable	20.96	24.74	21.88	22.01	30.21
Current Unearned Revenue	89.73	145.94	198.8	94.29	95.52
Other Current Liabilities	206.91	199.97	156.42	121.96	134.8
Total Current Liabilities	410.83	466.26	458.42	332.18	384.76
Long-Term Debt	0.05	1.45	3.35	13.49	4.43
Long-Term Leases	28.12	30.68	40.75	50.02	53.41
Long-Term Unearned Revenue	3.95	3.14	1.89	0.58	0.75
Long-Term Deferred Tax Liabilities	3.8	3.33	2.96	1.35	0.79
Other Long-Term Liabilities	47.05	79.28	58.83	53.27	54.09
Total Liabilities	494.32	584.54	566.98	451.14	498.53
Common Stock	87.18	74.44	74.44	74.44	74.44
Retained Earnings	540.03	472.5	419.15	374.65	385.26
Treasury Stock	-17.47	-17.47	-17.47	-13.51	-11.77
Comprehensive Income & Other	-28.35	-24.24	-23.09	-2.03	-0.99
Total Common Equity	581.39	505.24	453.04	433.57	446.95
Minority Interest	14.4	23.84	117.75	199.66	218.72
Shareholders' Equity	595.79	529.07	570.79	633.22	665.67
Total Liabilities & Equity	1,090	1,114	1,138	1,084	1,164
Total Debt	40.32	38.57	50.63	68.68	64.74
Net Cash (Debt)	305.98	339.1	283.22	425.12	425.8
Net Cash Growth	-9.77%	19.73%	-33.38%	-0.16%	467.44%
Net Cash Per Share	0.63	0.71	0.59	0.88	0.88
Filing Date Shares Outstanding	491.62	477.47	477.47	481.7	484.03
Total Common Shares Outstanding	491.62	477.47	477.47	482.25	484.03
Working Capital	165.91	193.22	192.32	400.61	404.34
Book Value Per Share	1.18	1.06	0.95	0.90	0.92
Tangible Book Value	578.8	502.54	447.73	433.41	445.56
Tangible Book Value Per Share	1.18	1.05	0.94	0.90	0.92
Land	4.35	4.5	4.53	5.14	5.23
Buildings	6.28	6.22	6.06	6.65	6.88
Machinery	31.94	30.52	28.89	29.18	35.68
Order Backlog	349	-	-	-	447

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.